Study to find out whether immunosuppressant Mycophenolate Sodium is effective in the treatment of Covid 19 infection.
Not Applicable
Completed
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereHealth Condition 2: R688- Other general symptoms and signs
- Registration Number
- CTRI/2021/01/030477
- Lead Sponsor
- Shri Janai Research Foundation
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 212
Inclusion Criteria
1. Subjects with active COVID ââ?¬â?? 19 infection.
2. Age more than 18 years.
3. Actual or estimated weight more than 50kg.
4. Mild to moderate infection.
5. Subjects willing to give consent for participation in the study.
6. No clinical contraindications for Mycophenolate administration.
Exclusion Criteria
1. Age less than 18 years.
2. Subjects not willing to give consent for participation in the study.
3. Subjects having pancytopenia.
4. Subjects with secondary bacterial sepsis.
5. Subjects already taking immunosuppressive medications for other conditions.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess the effect of Mycophenolate on mortality due to COVID-19 infection.Timepoint: 30 days
- Secondary Outcome Measures
Name Time Method To assess the effect of Mycophenolate on need of hospitalization, inflammatory markers, length of hospital stay, length of ICU stay and economic burden of the treatment of the COVID ââ?¬â?? 19 infection. <br/ ><br>To assess the safety of Mycophenolate when used in the treatment of COVID ââ?¬â?? 19 infection. <br/ ><br> <br/ ><br>Timepoint: 30 days